Moderna says its vaccine is 93% effective against symptomatic illness at six months (though this data collection ended before delta emerged in the U.S.). Moderna said its booster candidates also ...

CAMBRIDGE, Mass. - Moderna’s COVID-19 vaccine remained 93% effective against symptomatic illness six months after the second dose, but amid the ongoing spread of the highly contagious delta variant, ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from ...

A new preprint study suggests that Moderna’s COVID-19 vaccine may be significantly more effective against symptomatic disease from the delta variant compared to Pfizer-BioNTech’s vaccine, while the ...

Oct 4 (Reuters) - Moderna (MRNA.O), opens new tab on Wednesday said its combination vaccine to protect against both COVID-19 and influenza generated a strong immune response compared to individual ...

Sept 6 (Reuters) - Moderna MRNA.O on Wednesday said clinical trial data showed its updated COVID-19 vaccine will likely be effective against the highly-mutated BA.2.86 subvariant of the coronavirus ...

Moderna said its combination vaccine targeting Covid and the flu was more effective than existing standalone shots for those viruses in a late-stage trial. The biotech company is the first to release ...

Moderna could know if its COVID-19 vaccine is safe and effective within a few weeks, according to a Sept. 17 report from The Boston Globe. The country’s declining infection rate makes it more ...

Moderna (NASDAQ:MRNA) said Thursday that preliminary clinical data has confirmed its updated COVID-19 vaccine generates a robust immune response against the EG.5 and FL 1.5.1 variants. The company ...

Stream NBC 5 for free, 24/7, wherever you are. Moderna on Monday said its combination vaccine that targets both Covid-19 and the flu was more effective than existing standalone shots for those viruses ...